Role of cytotechnologists in rapid onsite adequacy assessment of cytology materials for diagnostic workup and specimen allocation for ancillary testing using a standardized protocol.
Ancillary Services, Hospital
Biomarkers, Tumor
Biopsy, Fine-Needle
/ psychology
Biopsy, Large-Core Needle
/ psychology
Bone and Bones
/ pathology
Data Accuracy
Female
Hospitals, University
Humans
Laboratories, Hospital
/ standards
Lung
/ pathology
Male
Medical Laboratory Personnel
/ psychology
Neoplasms
/ diagnosis
Retrospective Studies
Specimen Handling
/ methods
Triage
/ methods
Ancillary testing
Cytotechnologist
Rapid on-site evaluation
Journal
Journal of the American Society of Cytopathology
ISSN: 2213-2945
Titre abrégé: J Am Soc Cytopathol
Pays: United States
ID NLM: 101613234
Informations de publication
Date de publication:
Historique:
received:
24
05
2019
revised:
23
07
2019
accepted:
13
08
2019
pubmed:
24
9
2019
medline:
4
6
2021
entrez:
24
9
2019
Statut:
ppublish
Résumé
Data on the performance of cytotechnologists in assessing specimen adequacy of needle core biopsies (NCB) is scant and their role in specimen triaging for ancillary studies have not been well established. We retrospectively analyzed rapid onsite evaluation (ROSE) performed exclusively by cytotechnologists on 248 NCB and fine-needle aspiration (FNA) specimens. Overall adequacy and accuracy rates were determined by comparing to final diagnosis. We also reviewed the process of specimen allocation for ancillary testing to determine whether specimens were appropriately triaged at the time of ROSE. Of the 248 cases, 222 (89.5%) were touch imprint and 26 (10.5%) were FNA smears. The overall adequacy rate was 73.4% (182 of 248). Concordance for "adequate" interpretation by ROSE with unequivocal malignant or benign diagnoses on final interpretation was 95.6%. The sensitivity, specificity, and accuracy of ROSE for a final "positive for malignancy" were 89.2% (95% CI 83.04% to 93.69%), 43.24% (95% CI 31.77% to 55.28%), and 73.87% (95% CI 67.57% to 55.28%), respectively. Cases with "positive for malignancy" on final diagnosis were "adequate" by ROSE in 89.1% (132 of 148) and "inadequate" in 10.8% (16 of 148), P < 0.0001. Ancillary tests were performed in 168 of 248 (67.7%); the majority were immunohistochemical stains for determining tumor subtype. Predictive biomarkers were performed successfully in 100% of metastatic breast cancers. Cytotechnologists performed at a high level of competency in providing ROSE and allocating specimens for ancillary testing, which were performed successfully in the majority of cases. Implementation of a standardized protocol for tissue management/prioritization is of paramount importance to maximize tissue preservation and minimize wastage.
Identifiants
pubmed: 31543473
pii: S2213-2945(19)30130-9
doi: 10.1016/j.jasc.2019.08.005
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
67-75Informations de copyright
Copyright © 2019 American Society of Cytopathology. Published by Elsevier Inc. All rights reserved.